d4T: keep it or abandon it?
By: Andrew Hill
Abstract
Stavudine is a nucleoside analogue used widely for first-line treatment of HIV in developing and middleincome countries. The World Health Organization recommended that all patients should switch to stavudine (30mg BID). However, there is evidence from the dose-ranging trials that patients with body weight below 60kg should use a dose of 20mg BID. For patients who show adverse events on stavudine, a switch to other nucleoside analogues can be considered. This article reviews d4T to study if it should be kept or abandoned.
Language: English
Page range: 541 - 546
Published online: Apr 13, 2018
Published in print: Aug 1, 2010
Published by: Chulalongkorn University
In partnership with: Paradigm Publishing Services
Keywords:
Related subjects:
© 2018 Andrew Hill, published by Chulalongkorn University
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.